← Polymarket

FDA moves BPC-157 to Category 1 by…?

Open

Selected outcome

December 31, 2026

wide spread 17–83%

December 31, 2026

Stored quote · checking the venue

Scheduled end
Dec 31, 2026 ET

Price

December 31, 2026

Loading price history.

Markets

  • December 31, 2026

    Will the FDA reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by December 31, 2026?

    No quote

    Open · $0 24h · $2,783 vol

    wide spread 17–83%

    Bid 17¢ · Ask 83¢

    Open full market view →
Event statistics
24h vol
$0
Volume
$4,785
Liquidity
$115
Open int.
—

How this resolves

Scheduled end
Dec 31, 2026 ET
  1. Trading
  2. Closed
  3. In review
  4. Resolved
Rules text

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.

View on Polymarket